Sistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSPFERNANDES, Caio J.CALDERARO, DanielaPILOTO, BrunaHOETTE, SusanaJARDIM, Carlos Vianna PoyaresSOUZA, Rogerio2019-11-062019-11-062019THERAPEUTIC ADVANCES IN RESPIRATORY DISEASE, v.13, article ID 1753466619878550, 13p, 20191753-4658https://observatorio.fm.usp.br/handle/OPI/33954Most physicians understand venous thromboembolism (VTE) to be an acute and time-limited disease. However, pathophysiological and epidemiological data suggest that in most patients VTE recurrence risk is not resolved after the first 6 months of anticoagulation. Recurrence rates are high and potentially life-threatening. In these cases, it would make sense to prolong anticoagulation for an undetermined length of time. However, what about the bleeding rates, induced by prolonged anticoagulation? Would they not outweigh the benefit of reducing the VTE recurrent risk? How long should anticoagulation be continued, and should all patients suffering from VTE be provided with extended anticoagulation? This review will address the most recent data concerning extended anticoagulation in VTE secondary prophylaxis. The reviews of this paper are available via the supplementary material section.engopenAccessdeep vein thrombosisdirect oral anticoagulantsextended anticoagulationprovokedpulmonary embolismtreatmentunprovokedvenous thromboembolismdeep-vein thrombosisintensity warfarin therapypulmonary-embolismsecondary prevention1st episodelong-termriskaspirincancerrecurrencearticleCopyright SAGE PUBLICATIONS LTD10.1177/1753466619878556Respiratory System1753-4666